Navigation Links
Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Date:8/19/2007

VANCOUVER, Aug. 15 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing additional diameters of its Quill(TM) Self-Retaining System (SRS) Polydioxanone (PDO) product line.

The Quill(TM) SRS PDO is a longer-lasting absorbable suture, which is typically used for deeper tissue closures. Angiotech is now able to offer a broad range of PDO suture products with diameters ranging from sizes 2 to 4-0.

"We are pleased to be able to market these new diameters of PDO sutures. As we have indicated, we intend to continue to expand the Quill(TM) SRS product line to cover multiple procedures for wound closure and tissue approximation," added Dr. Hunter.

Angiotech plans to exhibit the Quill(TM) SRS product line at the Annual Meeting of the American Society of Plastic Surgeons (ASPS) to be held on October 26-31, 2007 in Baltimore, MD.

About the Quill(TM) Self-Retaining System (SRS)

The innovative Quill(TM) SRS represents the next generation of wound closure technology. A patented helical barbed design enables surgeons to suture without the use of knots. The absence of knots provides a wide range of clinical and economic benefits, including:

Potential to improve patient outcomes:

- Minimizes complications associated with knots

- Potential to improve wound healing

- May enhance cosmesis

Potential to save time in the operating room:

- Achieves potentially significant time savings, especially in suture

intensive procedures

Enhanced procedural techniques:

- Allows closure of difficult wounds

- Enables suturing in tight places

- Allows the surgeon to control tension

Note on Forward Looking Statements

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements in this release include but are not limited to statements regarding; financial benefits to Angiotech that could potentially be realized from Angiotech's wound closure business, the ability of Angiotech to commercialize the Quill(TM) SRS product and to develop and commercialize any successive product lines, that a substantial market exists for the product, that the product will perform as expected, that the product represents an improvement over current wound closure methods and that these improvements could be beneficial to physicians and to patients. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include; poor performance of the product in the clinical setting; adverse events related to the use of the product; improper estimation of the size of the wound closure market; adverse results or unexpected delays in clinical development processes; our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to integrate into our business the operations of American Medical Instruments Holdings, Inc. and our ability to achieve the operational and other synergies and the other commercial or financial benefits expected as a result of that acquisition; and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this prospectus to reflect future results, events or developments.

Quill(TM) is a trademark of Quill Medical, Inc,, a wholly-owned

subsidiary of Angiotech Pharmaceuticals, Inc.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Jodi Regts, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, jregts@angio.com; Analysts and Investors: Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/31/2019)... , ... December 31, 2019 , ... ... expanding its pharmaceutical product development lab in Maryland. Emphasis will be ... size and expanded capabilities, Vici Health Sciences will be well positioned to meet ...
(Date:12/23/2019)... HARBOR, N.J. (PRWEB) , ... December 23, 2019 ... ... helium based leak detection systems for the Pharmaceutical, Biotechnology and Medical Device Industries, ... technical presenter at the Parenteral Drug Association (PDA) Container Closure Integrity Testing ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... received FDA 510(k) clearance for its latest CAPERE® Thrombectomy System for peripheral ... the CAPERE® offers great benefits for first-in-line treatment for nonsurgical removal of ...
(Date:12/4/2019)... ... December 04, 2019 , ... Improved Pharma’s analytical ... amorphous materials. Additionally, their PDF Synchrotron methods provide a way to determine the ... both in regulatory and patent applications.  , The latest developments were recently shared ...
Breaking Biology Technology:
(Date:12/4/2019)... , ... December 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using ...
(Date:11/27/2019)... ... November 25, 2019 , ... Though the forecast for the Thanksgiving holiday might ... travelers expected to hit the roads and the skies. It’s a new personal recipe ... oil will offer a simple design, mouth-watering pictures of food, an optional social component ...
(Date:11/22/2019)... ... 2019 , ... The inventors of a new and unique ... step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, ... Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM ...
Breaking Biology News(10 mins):